Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chlorogenic acid in preparing drugs for prevention and treatment of primary cutaneous T-cell lymphoma

A chlorogenic acid, primary technology, applied in drug combinations, antineoplastic drugs, pharmaceutical formulations, etc.

Active Publication Date: 2015-05-20
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF9 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no report on the use of chlorogenic acid in the treatment of primary cutaneous T-cell lymphoma.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chlorogenic acid in preparing drugs for prevention and treatment of primary cutaneous T-cell lymphoma
  • Application of chlorogenic acid in preparing drugs for prevention and treatment of primary cutaneous T-cell lymphoma
  • Application of chlorogenic acid in preparing drugs for prevention and treatment of primary cutaneous T-cell lymphoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 Targeting CD4 T lymphocytes in the treatment of primary cutaneous T cell lymphoma

[0032] (1) Animal model establishment and grouping

[0033] Mouse primary cutaneous T-cell lymphoma model, select adult BABL / c mice, male, 18-22g. During the experiment, take the well-grown tumor tissue, cut it into pieces, grind it, filter it, and dilute it with sterile normal saline at a ratio of 1:3 to make a tumor cell suspension, and inoculate 0.2ml of the tumor cell suspension on the back of the armpit of each mouse . The next day after inoculation, the animals were randomly divided into 8 groups, namely: (1) negative control group (normal saline group, NS), (2) chlorogenic acid administration group (CHA, 5 mg / kg), (3) Chlorogenic acid administration group (CHA, 10mg / kg), (4) Chlorogenic acid administration group (CHA, 20mg / kg), (5) Interferon administration group (IFN-γ), (6) Chlorogen Acid and interferon administration group (CHA+IFN-γ, 5mg / kg), (7) Chlorogenic acid ...

Embodiment 2

[0046] Example 2 Targeting CD8 T lymphocytes in the treatment of primary cutaneous T cell lymphoma

[0047] (1) Animal model establishment and grouping

[0048] Mouse primary cutaneous T-cell lymphoma model, select adult BABL / c mice, male, 18-22g. During the experiment, take the well-grown tumor tissue, cut it into pieces, grind it, filter it, and dilute it with sterile normal saline at a ratio of 1:3 to make a tumor cell suspension, and inoculate 0.2ml of the tumor cell suspension on the back of the armpit of each mouse . The next day after inoculation, the animals were randomly divided into 8 groups, namely: (1) negative control group (normal saline group, NS), (2) chlorogenic acid administration group (CHA, 5 mg / kg), (3) Chlorogenic acid administration group (CHA, 10mg / kg), (4) Chlorogenic acid administration group (CHA, 20mg / kg), (5) Interferon administration group (IFN-γ), (6) Chlorogen Acid and interferon administration group (CHA+IFN-γ, 5mg / kg), (7) Chlorogenic acid ...

Embodiment 3

[0061] Example 3 Experiment of chlorogenic acid on tumor suppression rate of primary cutaneous T-cell lymphoma

[0062] (1) Animal model establishment and grouping

[0063] Mouse primary cutaneous T-cell lymphoma model, select adult BABL / c mice, male, 18-22g. During the experiment, take well-grown tumor tissue, cut it into pieces, grind it, filter it, and dilute it with sterile normal saline at a ratio of 1:3 to make a tumor cell suspension, and inoculate 0.2ml of the tumor cell suspension on the back of each mouse’s armpit . On the second day after inoculation, the animals were randomly divided into 8 groups, namely: (1) negative control group (normal saline group, NS), (2) chlorogenic acid administration group (CHA, 5 mg / kg), (3) Chlorogenic acid administration group (CHA, 10mg / kg), (4) Chlorogenic acid administration group (CHA, 20mg / kg), (5) Interferon administration group (IFN-γ), (6) Chlorogen Acid and interferon administration group (CHA+IFN-γ, 5mg / kg), (7) Chlorogen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention aims to provide an application of chlorogenic acid in preparing drugs for prevention and treatment of primary cutaneous T-cell lymphoma. Experiments show that the chlorogenic acid can activate CD4 T-lymphocytes and CD8 T-lymphocytes, and prevent and treat primary cutaneous T-cell lymphoma by taking the CD4 T-lymphocytes and the CD8 T-lymphocytes as targets. According to the invention, the chlorogenic acid is adopted for promoting the proliferation of T-lymphocytes of a body and activating the T-lymphocytes so as to achieve the purpose of treating primary cutaneous T-cell lymphoma. Meanwhile, the chlorogenic acid also can inhibit the proliferation of primary cutaneous T-cell lymphoma cells, and the inhibition effect of the chlorogenic acid is similar to the inhibition effect of interferon.

Description

technical field [0001] The invention relates to the field of biomedicine, especially the field of treatment of primary cutaneous T-cell lymphoma, in particular the use of chlorogenic acid in the preparation of medicines for preventing and treating primary cutaneous T-cell lymphoma. Background technique [0002] Primary cutaneous T cell lymphoma (CTCL), formerly known as granuloma fungoid, is a cutaneous primary lymphoma. As a group of lymphoproliferative diseases with obvious heterogeneity, it lacks a standardized treatment plan. [0003] In the early stage of its onset, it is mainly to enhance the patient's immunity and local treatment, such as interferon, BCG or transfer factor, etc.; local treatment can be external application of nitrogen mustard or aromatic retinoic acid, electron beam irradiation, X-rays, and photochemotherapy etc. have a certain curative effect. At present, no new chemotherapy drugs and targeted therapy drugs have been reported for the treatment of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61K31/675A61K31/513A61K38/20A61K38/21A61P35/00
CPCA61K31/216A61K31/513A61K31/675A61K38/20A61K38/21
Inventor 张洁殷蕊蕊黄骏黄望
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com